These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33667538)

  • 1. Alopecia areata flare patterns in children and young adults while on systemic tofacitinib.
    McKenzie PL; Castelo-Soccio L
    J Am Acad Dermatol; 2022 Mar; 86(3):683-685. PubMed ID: 33667538
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients.
    Serdaroğlu S; Engin B; Çelik U; Erkan E; Aşkın Ö; Oba Ç; Kutlubay Z
    Dermatol Ther; 2019 May; 32(3):e12844. PubMed ID: 30693634
    [No Abstract]   [Full Text] [Related]  

  • 3. Response of alopecia areata of the beard to oral tofacitinib.
    Kerkemeyer KLS; John JM; Sinclair R; Bhoyrul B
    J Am Acad Dermatol; 2020 May; 82(5):1228-1230. PubMed ID: 31678329
    [No Abstract]   [Full Text] [Related]  

  • 4. Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection.
    Youssef S; Lavian J; Lee EY; Fan W; Bordone LA
    J Am Acad Dermatol; 2023 May; 88(5):1125-1127. PubMed ID: 35551958
    [No Abstract]   [Full Text] [Related]  

  • 5. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
    Liu LY; Craiglow BG; King BA
    J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
    [No Abstract]   [Full Text] [Related]  

  • 6. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
    Benton S; Farah R; Freese R; Hordinsky M
    Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
    Liu LY; Craiglow BG; Dai F; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review - alopecia areata and tofacitinib in paediatric patients.
    Bandeira A; Albino-Teixeira A; Magina S
    Cutan Ocul Toxicol; 2022 Jun; 41(2):194-201. PubMed ID: 35687530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
    Craiglow BG; Liu LY; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

  • 11. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata.
    Akdogan N; Ersoy-Evans S; Doğan S; Atakan N
    Dermatol Ther; 2019 Nov; 32(6):e13118. PubMed ID: 31621150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib for Treatment of Alopecia Areata: Real-world Evidence and Factors Associated with Therapeutic Response.
    Sanchez-Diaz M; Diaz-Calvillo P; Rodriguez-Pozo JA; Tercedor-Sánchez J; Cantudo-Cuenca MR; Molina-Leyva A; Arias-Santiago S
    Acta Derm Venereol; 2022 Jun; 102():adv00736. PubMed ID: 35578820
    [No Abstract]   [Full Text] [Related]  

  • 14. [Alopecia areata with good response to tofacitinib].
    Maksimow A; Stintzing D; Wohlrab J
    Hautarzt; 2021 Jun; 72(6):525-527. PubMed ID: 33044559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
    Cheng MW; Kehl A; Worswick S; Goh C
    J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developing multiple sclerosis in a patient using tofacitinib due to alopesia areata.
    Erçoban R; İslamoğlu ZGK
    Dermatol Ther; 2022 Jun; 35(6):e15477. PubMed ID: 35355384
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral tofacitinib for the treatment of alopecia areata in pediatric patients.
    Kibbie J; Kines K; Norris D; Dunnick CA
    Pediatr Dermatol; 2022 Jan; 39(1):31-34. PubMed ID: 34779041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib therapy for children with severe alopecia areata.
    Dai YX; Chen CC
    J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026
    [No Abstract]   [Full Text] [Related]  

  • 19. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis.
    Putterman E; Castelo-Soccio L
    J Am Acad Dermatol; 2018 Jun; 78(6):1207-1209.e1. PubMed ID: 29754888
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.